Effect of NLRP3 inflammasome genes polymorphism on disease susceptibility and response to TNF-α inhibitors in Iraqi patients with rheumatoid arthritis

Effect of NLRP3 inflammasome genes polymorphism on disease susceptibility and response to TNF-α inhibitors in Iraqi patients with rheumatoid arthritis

Background: Rheumatoid arthritis (RA) is a genetically predisposed, systemic, chronic, inflammatory disease. Immune system dysregulation and inherited susceptibility polymorphisms suggest that this type of variation is functional and may help predict disease susceptibility and develop new therapeuti...

Full description

Bibliographic Details
Main Authors:	Abdullah Abbas Awni, Zainab Oday Hamed, Ahmed Abdul-Hassan Abbas, Ahmed Sahib Abdulamir
Format:	Article
Language:	English
Published:	Elsevier 2023-06-01
Series:	Heliyon
Subjects:	Rheumatoid arthritis Etanercept Infliximab IL-1β TNF-α NLRP3
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844023040215

Similar Items

The Role of Anti-TNFα Therapy in the Amelioration of Disease Burden in Patients with Refractory Rheumatoid Arthritis
by: Madha Mohammed Sheet, et al.
Published: (2014-06-01)

Contribution of Toll-Like Receptors and the NLRP3 Inflammasome in Rheumatoid Arthritis Pathophysiology
by: Unterberger S, et al.
Published: (2021-07-01)

Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα Immediate complications of 3,555 injections of anti-TNFα
by: Júlio César Bertacini de Moraes, et al.
Published: (2010-04-01)

Immunologic Parameters for Disease Activity in Rheumatoid Arthritis
by: E Riyadh Mohsen, et al.
Published: (2021-10-01)

Correlation of anti-TNF-a biological therapy with periodontal conditions and osteonecrosis in autoimmune patients: A systematic review
by: Rana Majdi Abunemer, et al.
Published: (2023-11-01)

Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review
by: Vidhi V. Shah, et al.
Published: (2018-08-01)

Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα
by: Júlio César Bertacini de Moraes, et al.

Terapia com anti-TNF na amiloidose renal em artrite reumatoide refratária: uma nova perspectiva terapêutica Anti-TNF therapy in renal amyloidosis in refractory rheumatoid arthritis: a new therapeutic perspective
by: Christiane Aguiar Nobre, et al.
Published: (2010-04-01)

Role of NLRP3 Inflammasome in Rheumatoid Arthritis
by: Hui Yin, et al.
Published: (2022-06-01)

Safety and efficiency of therapy by gene-engineering-biological preparations of rheumatoid arthritis
by: E. A. Strel’tsov
Published: (2018-10-01)

Corrigendum: Role of NLRP3 inflammasome in rheumatoid arthritis
by: Hui Yin, et al.
Published: (2023-07-01)

Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.
by: Mohammed A. Al-Karkhi, et al.
Published: (2015-10-01)

Predictors of Response to (Etanercept) in the Treatment of Iraqi Patients with Active Rheumatoid Arthritis
by: Nizar A. Jassim
Published: (2015-04-01)

HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE
by: A. S. Kolbin, et al.
Published: (2016-12-01)

Role of Etanercept and Infliximab on Nociceptive Changes Induced by the Experimental Model of Fibromyalgia
by: Marika Cordaro, et al.
Published: (2022-05-01)

Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis
by: Cristina Membrive-Jiménez, et al.
Published: (2023-05-01)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
by: Evelien Moorkens, et al.
Published: (2020-10-01)

Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders
by: S Oertle, et al.
Published: (2002-07-01)

The Effect of TNF-Alpha Gene Polymorphisms At -376 G/A, -806 C/T, and -1031 T/C on The Likelihood of Becoming a Non-Responder to Etanercept in A Sample of Iraqi Rheumatoid Arthritis Patients
by: Samer Imad Mohammed, et al.
Published: (2022-12-01)

Estimation levels of CTHRC1and some cytokines in Iraqi patients with Rheumatoid Arthritis
by: Ahmed R. Oleiwi, et al.
Published: (2023-06-01)

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence
by: Iannone F, et al.
Published: (2022-06-01)

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
by: Yoshiya Tanaka, et al.
Published: (2019-07-01)

Association between genetic polymorphism in tumor necrosis factor-alpha gene and adverse effects of etanercept in rheumatoid arthritis patients
by: Samer Imad Mohammed, et al.
Published: (2023-09-01)

Epidemiological and Clinical Factors Affecting the Response to Etanercept Among Patients with Rheumatoid Arthritis
by: Samer Imad Mohammed, et al.
Published: (2022-06-01)

Influence of promoter polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) genes on therapeutic response to etanercept in rheumatoid arthritis
by: Jančić Ivan, et al.
Published: (2015-01-01)

Tratamiento biológico en psoriasis: Revisión bibliográfica Biologic therapy of psoriasis: Literature review
by: MS Lorenzetti, et al.
Published: (2012-06-01)

THE PROBLEMS OF THE SAFETY OF THERAPY WITH TUMOR NECROSIS FACTOR-а INHIBITORS
by: Dmitry Evgenyevich Karateyev
Published: (2009-09-01)

Incidencia de tuberculosis en pacientes que reciben fármacos anti-TNFα
by: Ana Gruss, et al.
Published: (2020-03-01)

The Role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in Personalized Treatment of Patients with Isolated Polymyalgia Rheumatica (PMR): Past and Possible Future Scenarios
by: Ciro Manzo, et al.
Published: (2022-02-01)

Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases
by: Loris Riccardo Lopetuso, et al.
Published: (2023-05-01)

Comparative Efficacy and Acceptability of Anti-TNF-Alpha Therapy in Ankylosing Spondylitis: A Mixed-Treatments Comparison
by: Yehua Wang, et al.
Published: (2016-09-01)

Gene Expression of NLRP3 Inflammasome in Celiac Disease of Iraqi Children
by: Anwar I. S. Al-Assaf, et al.
Published: (2021-06-01)

The Role of Non-Selective TNF Inhibitors in Demyelinating Events
by: Line Buch Kristensen, et al.
Published: (2021-01-01)

The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort
by: Mai Nasser Abd ElMohsen, et al.
Published: (2023-01-01)

Mitochondrion-NLRP3 inflammasome activation in macrophages: A novel mechanism of the anti-inflammatory effect of Notopterygium in rheumatoid arthritis treatment
by: Xiangxiang Liu, et al.
Published: (2023-11-01)

INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-03-01)

Effectiveness of Combination of Leflunomide and Methotrexate compared to Etanercept in the Treatment of Rheumatoid Arthritis: A systematic review and meta-analysis
by: Rashin Iman, et al.
Published: (2021-07-01)

Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
by: Yen-Ju Lin, et al.
Published: (2020-04-01)

Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis
by: Szilárd Póliska, et al.
Published: (2019-04-01)

Gene Expression and Polymorphism of Interleukin-4 in a Sample of Iraqi Rheumatoid Arthritis Patients
by: Baghdad Science Journal
Published: (2018-06-01)